UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended December 31, 2018
[  ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from __________  to __________
	Commission File Number: 333-156091

 

Alterola Biotech, Inc.

(Exact name of Registrant as specified in its charter)

 

Nevada	TBA
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

 

340 S Lemon Ave # 4041 Walnut, California 91789

(Address of principal executive offices)

 

512-821-2121

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[ ] Yes [X] No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] Yes [ ] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

 

[  ] Large accelerated filer	[  ] Accelerated filer
[  ] Non-accelerated filer	[X] Smaller reporting company
	[  ] Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[X] Yes [ ] No

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 330,980,000 shares as of December 22, 2020. 

 

 

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	6
Item 4:	Controls and Procedures	6
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	7
Item 1A:	Risk Factors	7
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	7
Item 3:	Defaults Upon Senior Securities	7
Item 4:	Mine Safety Disclosure	7
Item 5:	Other Information	7
Item 6:	Exhibits	7

 

 

PART I - FINANCIAL INFORMATION

 

Item 1.     Financial Statements

 

Our financial statements included in this Form 10-Q are as follows:

 

F-1	Balance Sheets as of December 31, 2018 and September 30, 2018 (unaudited);

 

F-2	Statements of Operations for the three months ended December 31, 2018 and 2017 (unaudited);

 

F-3	Statements of Cash Flow for the three months ended December 31, 2018 and 2017 (unaudited);

 

F-4	Notes to Financial Statements.

 

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities Exchange Commission (“SEC”) instructions to Form 10-Q.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  Operating results for the interim period ended December 31, 2018 are not necessarily indicative of the results that can be expected for the full year.

 

 

ALTEROLA BIOTECH, INC.

BALANCE SHEETS

AS OF DECEMBER 31, 2018 AND SEPTEMBER 30, 2018

 

 

 

		December 31, 2018 (unaudited)				September 30, 2018
ASSETS
Current Assets
Funds held in attorney trust		$	14,742			$	14,742
Deferred stock compensation			9,000				36,000
Total current assets			23,742				50,742
TOTAL ASSETS		$	23,742			$	50,742
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable		$	18,136			$	24,249
Accrued interest			—				1,360
Accrued directors fees			90,000				60,000
Advances from related party			2,250				750
Current portion of notes payable			0				0
Total Current Liabilities			110,386				86,359
Non current portion of notes payable			0				19,950
Total Liabilities			110,386				106,309
Stockholders’ Deficit
Preferred Stock, $.001 par value, 10,000,000 shares authorized, -0- shares issued and outstanding			—				—
Common Stock, $.001 par value, 140,000,000 shares authorized, 115,980,000 shares issued and outstanding			115,980				115,980
Additional paid-in capital			562,587				541,028
Deficit accumulated			(765,211	)			(712,575)
Total Stockholders’ Deficit			(86,644	)			(55,567)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT		$	23,742			$	50,742

 

See accompanying notes to financial statements.

 

 

ALTEROLA BIOTECH, INC.

STATEMENTS OF OPERATIONS (unaudited)

FOR THE THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017

 

		Three months ended
		December 31, 2018				December 31, 2017
REVENUES		$	0			$	0
OPERATING EXPENSES
Stock based compensation			27,000				0
Accounting and audit fees			250				250
Legal fees			(5,208	)			1,000
Directors fees			30,000				0
General and administrative expenses			345				0
TOTAL OPERATING EXPENSES			52,387				1,250
LOSS FROM OPERATIONS			(52,387	)			(1,250)
OTHER INCOME (EXPENSE)
Interest expense			(249	)			(4,625)
TOTAL OTHER INCOME (EXPENSE)			(249	)			(4,625)
PROVISION FOR INCOME TAXES			0				0
NET INCOME (LOSS)		$	(52,636	)		$	(5,875)
NET INCOME (LOSS) PER SHARE: BASIC AND DILUTED		$	(0.00	)		$	(0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED			115,980,000				114,980,000

 

See accompanying notes to financial statements.

 

 

ALTEROLA BIOTECH, INC.

STATEMENT OF STOCKHOLDERS’ DEFICIT (unaudited)

FOR THE PEROD ENDED DECEMBER 31, 2018

 

			Common stock
			Shares				Amount				Additional paid-in capital				Accumulated Deficit				Total
Balance, September 30, 2015			114,980,000				114,980				132,850			$	(489,299	)		$	(241,469)
Net loss for the year ended September 30, 2016			—				—				—				(22,577	)			(22,577)
Balance, September 30, 2016			114,980,000				114,980				132,850				(511,876	)			(264,046)
Common stock surrendered for voluntary cancellation			(37,000,000	)			(37,000	)			37,000				0				0
Common stock issued for services			37,000,000				37,000												37,000
Net loss for the year ended September 30, 2017			—				—				—				(67,632	)			(67,632)
Balance, September 30, 2017			114,980,000				114,980				169,850				(579,508	)			(294,678)
Common stock issued for services			1,000,000				1,000				89,000								90,000
Capital contribution from forgiveness of debt											282,178								282,178
Net income (loss) for the period ended September 30, 2018															(133,067	)			149,111
Balance, September 30, 2018			115,980,000			$	115,980			$	541,028			$	(712,575	)		$	(55,567)
Capital contribution from forgiveness of debt											21,559								21,559
Net income (loss) for the period ended December 31, 2018															(52,636	)			(52,636)
Balance, December 31, 2018			115,980,000			$	115,980			$	562,587			$	(765,211	)		$	(86,644)

 

See accompanying notes to financial statements.

 

 

ALTEROLA BIOTECH, INC.

STATEMENTS OF CASH FLOWS (unaudited)

FOR THE THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017

 

		Three months ended
		December 31, 2018				December 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss) for the period		$	(52,636	)		$	(5,875)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation			27,000				0
Changes in assets and liabilities:
Increase (decrease) in accrued expenses			23,887				1,250
Increase (decrease) in accrued interest			249				4,625
Increase (decrease) in advance from related party			1,500				0
Net Cash Used by Operating Activities			0				0
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of intellectual property			0				0
Website development			0				0
Net Cash Used by Investing Activities			0				0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable			0				0
Net Cash Provided by Financing Activities			0				0
Net Increase (Decrease) in Cash and Cash Equivalents			0				0
Cash and cash equivalents, beginning of period			0				0
Cash and cash equivalents, end of period		$	0			$	0
SUPPLEMENTAL CASH FLOW INFORMATION
Interest paid		$	0			$	0
Income taxes paid		$	0			$	0
NON-CASH INVESTING AND FINANCING INFORMATION
Deferred financing costs related to notes payable		$	0			$	0

 

See accompanying notes to financial statements.

 

   

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

DECEMBER 31, 2018

 

NOTE 1 – NATURE OF BUSINESS

 

Alterola Biotech, Inc. (“Alterola” and the “Company”) is a development stage company and was incorporated in Nevada on July 21, 2008. The Company was formed to acquire exploration and development stage mineral properties.

 

On October 1, 2008, the Company incorporated JRE Exploration Ltd, (“JRE”) a wholly owned subsidiary in Canada to hold its Canadian mineral claims.

 

On May 3, 2010, the Company changed its focus to the development of intellectual property and accordingly sold JRE to the former president. In keeping with the change of business focus, on July 9, 2010, the Company changed its name to Alterola Biotech Inc.

 

In April 2017, the Company entered into an assignment agreement with its director to convey all assets and intellectual property to its former director for the cancellation of 37,000,000 shares of the Company.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Basis

The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting).  The Company has a September 30 fiscal year end.

 

Basis of Presentation

The accompanying unaudited interim financial statements of Alterola Biotech Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s registration statement filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for the financial statements to be not misleading have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for the most recent fiscal year 2018 as reported in Form 10-K, have been omitted.

 

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Equivalents

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.

 

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

DECEMBER 31, 2018

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Funds held in attorney trust

The company does not have its own bank account. Amounts due from attorney represents fund held on behalf of the Company in trust by its legal counsel.

 

Fair Value of Financial Instruments

Alterola’s financial instruments consist of cash and equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

 

FV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk.

 

In addition to defining FV, the disclosure requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are:

 

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

 

Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

  

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

DECEMBER 31, 2018

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Fair Value of Financial Instruments (continued)

Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The FV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 

The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

 

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

Revenue Recognition

On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended September 30, 2018, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605.

 

Loss Per Common Share

Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

 

Stock-Based Compensation

Stock-based compensation is accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options

 

During the year ended September 30, 2018, the Company issued 1,000,000 shares of common stock to an officer for services rendered with a deemed value of services provided of $90,000 for services rendered from April 1, 2018 to January 31, 2019. As of December 31, 2018, $9,000 of stock-based compensation has been recorded as a prepaid expense.

 

Recent Accounting Pronouncements

Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

 

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

DECEMBER 31, 2018

 

NOTE 3 – ACCOUNTS PAYABLE

 

Accounts payable consisted of the following at December 31, 2018 and September 30, 2018:

 

		December				September
Audit fees		$	0			$	1,000
Accounting			4,850				4,350
Legal fees and transfer agent			13,286				18,899
Total accounts payable		$	18,136			$	24,249

 

NOTE 4 – NOTES PAYABLE

 

Notes payable consisted of the following at December 31, 2018 and September 30, 2018:

 

		December 31, 2018				September 30, 2018
Note payable, secured by assets of the company, bearing interest at 5% due on April 25, 2023			0				19,950
			0				19,950
Less: current portion			(0	)			(0)
Total notes payable		$	0			$	19,950

 

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

DECEMBER 31, 2018

 

NOTE 4 – NOTES PAYABLE (CONTINUED)

 

The Convertible note was convertible at the option of the holder. The number of shares of common stock into which the convertible note was to be converted is determined by the Fair Market Price (“FMV”) of the common stock at the date of conversion. In the event there is no determinable market price the FMV shall be:

 

a) The share price at the last private offering of the common stock, or, b) the 30 day moving average of the Common Stock in the event a public listing of the common stock has taken place.

 

Interest expense was $249 and $4,625 for the periods ended December 31, 2018 and 2017, respectively.

 

On March 28, 2018 the Company entered into agreements with its debt holders to forgive promissory notes and accrued interest of $ 282,178. As a result, the Company has reclassified debt and interest payable to additional paid in equity for $ 282,178 in the financial statements for the year ended September 30, 2018. On December 31, 2018 the Company entered into agreements with a debt holder to forgive additional promissory notes and accrued interest of $21,559. As a result, the Company has reclassified debt and interest payable to additional paid in equity for $21,559 in the financial statements for the period ended December 31, 2018,

 

NOTE 5 – CAPITAL STOCK

 

The Company has 140,000,000 shares of $0.001 par value common stock authorized and 10,000,000 shares of $0.001 par value preferred stock authorized.

 

On April 10, 2017, a former director of the Company surrendered for voluntary cancellation, 37,000,000 shares of common stock with a deemed value of $ 37,000.

 

On April 10,2017, the Company issued 37,000,000 shares of common stock to its director for services with a deemed value of $ 37,000.

 

On June 28, 2018 the company issued one million common shares for consulting services with a deemed value of $90,000. As the services are to be provided over a period from April 1, 2018 to January 31, 2019, the company has recorded $9,000 as prepaid stock based compensation.

 

The Company has 115,980,000 and 115,980,000 shares of common stock issued and outstanding as of December 31, 2018 and September 30, 2018 respectively. There are no shares of preferred stock issued and outstanding as of December 31, 2018 and September 30, 2018.

 

NOTE 6- INCOME TAX

 

Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax asset. The income tax effects of the Tax Cuts and Jobs Act have been completed in accordance with FASB ASC 740.

 

 

NOTE 6 – INCOME TAXES (continued)

 

The provision for income tax consists of the following components at December 31, 2018 and 2017:

 

		2018				2017
Current:
Federal income taxes (benefit)			(17,896	)		$	(1,998)
State income taxes			—				—
Deferred Benefit from net operating loss			—				—
		$	—			$	(1,998)

 

The following reconciles income taxes reported in the financial statements to taxes that would be obtained by applying regular tax rates to income before taxes:

 

		2018				2017
Expected tax expense (benefit) using regular rates		$	17,896			$	1,998
State minimum tax
Valuation allowance			(17,896	)			(1,998)
Tax Provision		$	—			$	—

 

The Company has loss carry forwards totaling $817,457 that may be offset against future federal income taxes. If not used, the carry forwards will expire between 2028 and 2039.

 

At December 31, 2018 and September 30, 2018, the significant components of the deferred tax assets are summarized below:

 

		December 31,2018				September 30, 2018
Deferred income tax asset
Net operation loss carryforwards			277,935				260,039
Total deferred income tax asset			277,935				260,039
Less: valuation allowance			(277,935	)			(260,039)
Total deferred income tax asset		$	—			$	—

 

The federal income tax returns of the Company for 2018 and 2017 are subject to examination by the IRS, generally for three years after they were filed.

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Alterola neither owns nor leases any real or personal property. An officer has provided office space without charge. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future.

 

During the period ended December 31, 2018, the Company accrued director’s fees payable of $ 30,000.

 

  

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

DECEMBER 31, 2018

 

NOTE 8 – LIQUIDITY & GOING CONCERN

 

Alterola has negative working capital, has incurred losses since inception, and has not received revenues from sales of products or services. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

 

The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

 

NOTE 9 – SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855-10, the Company analyzed its operations subsequent to December 31, 2018 to the date these financial statements were issued.

 

On July 20, 2020, the Company appointed certain directors and officers. As part of the appointment, each individual received issuance of 1,000,000 shares of common stock, respectfully, valued at $10,000 per individual.

 

On September 4, 2020, the Company issued 6,000,000 shares of common stock to the newly appointed Chief Executive Officer and Director, as compensation for services to the Company, valued at $60,000.

 

On September 18, 2020, the Company issued 200,000,000 shares of common stock to Amsterdam Café Holdings Ltd, at a price of $0.001 per share, for total proceeds of $200,000.

 

On December 2, 2020, the board of directors accepted the resignations of Irving Aronson as Chairman and Director, Peter Maddocks as CFO and Director, Oliver Aubrey as Chief Medical Officer and Director, Rene Lauritsen as COO and Director, and Larson Elmore as CEO. Dr. Daniel Reshef and Lalit Kumar will remain as Directors of the Board. Mr. Elmore will continue as Vice Chairman, Director and Secretary of our company.

 

Also on December 2, 2020, we have appointed the following officers and directors: Tim Rogers as the CEO and Director, and Director, Dominic Schiller as Director & IP Counsel, Seamus McAuley as Chief Commercial Officer and Director, Daniel Reshef as Vice Chairman Medical Director and Zohar Koren as Advisory Medical Director.

 

 

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

The Board of Directors believes that it would be in the best interests of the company and its shareholders to embark upon a new business opportunity and to align with integrated companies that complement an expansion strategy.

 

The business plan will no longer be focused only on a chewing gum delivery system but rather to expand as a broad based business plan in the Cannabis sector.

 

The IP develops chewing gum to deliver nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant. Surrounding that line of business. The business plan of the company it to be expanded and repositioned in the CBD health sector focusing on acquisitions and alignments of companies with reoccurring cash flows. The plan is to develop and acquire CBD whole health pharma outlets and dispensaries sourcing cultivation opportunities worldwide.

 

As part of its expansion strategy the company is also interested in recruiting of key executives that have experience in the medical cannabis industry. The focus will be on those outstanding talents that have contributed or can contribute more in the future with our plan of expansion. The scope of the recruitment will be on talent that have proven product development skills such as scientists, doctors and horticultural genetics.

 

The company also has interest in acquiring other Medicinal IP companies that can addresses health related issues. It is intended that these IPs will be utilized to develop and produce products that will be sold in retail outlets. These products are also expected to be sold on our Online Web store.

 

Under consideration for our acquisition health product strategy are many companies that have existing tested broad-based brands. Some of these companies are available to consolidate into our company strategy. These acquisition opportunities have various contributions to a larger scope of applications, such as CBD formulations for coffee, tea, mocha treats, as well as health treatment topicals and even pet industry applications. Our intention is to offer these formulations.

 

 

The CBD pharmaceutical market worldwide has experienced exponential growth over the past few years in the development of products. The market has expanded with a wide range of dietary supplements, vitamins, minerals, herbals, non-herbals, among others, and functional CBD, foods and beverages.

 

The company is positioned to deliver infused CBD products through its intellectual property and formulations and to expand the business opportunity. The company is in the process of developing a fully integrated company that delivers to the market to distribute numerous pharmaceutical products improving people’s health with functional effects.

 

Alterola is especially interested in companies with IP, such as patent pending status, patents, trademarks, or copyrights that are significant and provide a market differential for health and wellness applications. Our strategic plan is to build an “added value” structure which increases our baseline margins.

 

At the center of all this, we have a need to offer only the absolute best NON-THC- broad spectrum products on a worldwide business plan. We do this by being mindful of pharmaceutical companies engaged in the formulation, development, and commercialization of various cannabinoid- based products which allow us to pivot where necessary to meet changing environments. While growing the company by expanding though acquisitions on a worldwide bases the company expects that it will have additional support to bring added value to fulfill the scope of the business plan.

 

Results of Operations for the Three Months Ended December 31, 2018 and 2017

 

We have generated no revenues since inception and we do not anticipate earning revenues until such time that we are able to market and sell our products.

 

We incurred operating expenses of $52,387 for the three months ended December 31, 2018, compared with $1,250 for the three months ended December 31, 2017. Our operating expenses for the three months ended December 31, 2018 mainly consisted of $30,000 in director fees and $27,000 in stock based compensation. Our operating expenses for the three months ended December 31, 2017 consisted of $1,000 in legal fees and $250 in accounting and audit fees.

 

We recorded other expenses of $249 for the three months ended December 31, 2018, which consisted of interest expense. We had other expenses of $4,625 in interest expense for the three months ended December 31, 2017.

 

We recorded a net loss of $52,636 for the three months ended December 31, 2018, compared with a net loss of $5,875 for the three months ended December 31, 2017.

 

Liquidity and Capital Resources

 

As of December 31, 2018, we had $23,742 in current assets and currently liabilities of $110,386. We had a working capital deficit of $86,644 as of December 31, 2018.

 

Operating activities used $0 in cash for the nine months ended December 31, 2018, compared with $0 for the comparable period ended December 31, 2017.

 

Financing activities provided $0 for the nine months ended December 31, 2018, compared with $0 for the period ended December 31, 2017.

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next 12 months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

 

Off Balance Sheet Arrangements

 

As of December 31, 2018, we had no off balance sheet arrangements.

 

Going Concern

 

Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred cumulative losses of $765,211 for the period July 21, 2008 (inception date) through December 31, 2018, expect to incur further losses in the development of our business and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Item 3.     Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4.     Controls and Procedures

 

Disclosure Controls and Procedures

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2018. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2018, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of December 31, 2018, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending September 30, 2021: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended December 31, 2018 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

 

  

PART II – OTHER INFORMATION

 

Item 1.     Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A:  Risk Factors

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

 

On July 20, 2020, the Company appointed certain directors and officers. As part of the appointment, each individual received issuance of 1,000,000 shares of common stock, respectfully.

 

On September 4, 2020, the Company issued 6,000,000 shares of common stock to the newly appointed Chief Executive Officer and Director, as compensation for services to the Company.

 

On September 18, 2020, the Company issued 200,000,000 shares of common stock to Amsterdam Café Holdings Ltd, at a price of $0.001 per share, for total proceeds of $200,000.

 

Item 3.     Defaults upon Senior Securities

 

None

 

Item 4.     Mine Safety Disclosures

 

Not applicable.

 

Item 5.     Other Information

 

On December 23, 2020, Larson Elmore was appointed interim Chief Financial Officer.

 

Item 6.      Exhibits

 

Exhibit Number	Description of Exhibit
10.1	Executive Employment Agreement, dated April 1, 2018
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2018 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	Alterola Biotech, Inc.
Date:	December 29, 2020
	By: /s/ Tim Rogers Tim Rogers Title:   Chief Executive Officer and Director